Carbapenemase-producing enterobacteriae: Epidemiology, strategies to control their spread and issues;Maîtrise de la diffusion des entérobactéries productrices de carbapénémases: Épidémiologie, stratégies de prévention et enjeux

Revue de Medecine Interne

Volumn 36, Issue 7, 2015, Pages 474-479

  Lepelletier, D ^a   Batard, E ^a   Berthelot, P ^b   Zahar, J R ^c   Lucet, J C ^d   Fournier, S ^e   Jarlier, V ^e,f   Grandbastien, B ^g  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d BICHAT HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Carbapenemase; Emergence; Highly resistant bacteria; Prevention

Indexed keywords

ARTICLE; ASYMPTOMATIC INFECTION; BACTERIUM CARRIER; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; COMMENSALISM; ENTEROBACTERIACEAE; ENTEROCOCCUS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INTESTINE FLORA; NONHUMAN; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; MULTIDRUG RESISTANCE; PROCEDURES;

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; INFECTION CONTROL;

EID: 84952637214     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2014.12.006     Document Type: Short Survey

References (40)

1. Levy S.B., O'Brien T.F. Antimicrobial resistance alerts and implications. Clin Infect Dis 2005, 41:S219-S220.
2. American Society For Microbiology Antibiotic resistance: an ecological perspective on an old problem 2009, http://www.asm.org/.
3. Livermore D.M. Has the era of untreatable infections arrived. J Antimicrob Chemother 2009, 64(Suppl 1):i29-i36.
4. Huttner A., Harbarth S., Carlet J., Cosgrove S., Goossens H., Holmes A., et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control 2013, 18(2):31.
5. Organisation mondiale de la santé La résistance aux antibiotiques 2014, Disponible sur http://www.euro.who.int/fr/health-topics/disease-prevention/antimicrobial-resistance/antibiotic-resistance.
6. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect 2014, 44:51-56.
7. Munoz-Price L.S., Poirel L., Bonomo R.A., Schwaber M.J., Daikos G.L., Cormican M., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013, 13:785-796.
8. EARS-Net Antimicrobial Resistance Interactive Database 2014, Disponible sur http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2011.pdf.
9. Fournier S., Monteil C., Lepainteur M., Richard C., Brun-Buisson C., Jarlier V., et al. Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012. Euro Surveill 2014, 19. pii: 20802.
10. Cuzon G., Naas T., Demachy M.C., Nordmann P. Nosocomial outbreak of Klebsiella pneumoniae harbouring bla(KPC-3) in France subsequent to a patient transfer from Italy. Int J Antimicrob Agents 2012, 39:448-449.
11. Carbonne A., Thiolet J.M., Fournier S., Fortineau N., Kassis-Chikhani N., Boytchev I., et al. Control of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae type 2 in France, September to October 2009. Euro Surveill 2010, 15. pii: 19734.
12. Crémet L., Bourigault C., Lepelletier D., Guillouzouic A., Juvin M.E., Reynaud A., et al. Nosocomial outbreak of carbapenem-resistant Enterobacter cloacae highlighting the interspecies transferability of the blaOXA-48 gene in the gut flora. J Antimicrob Chemother 2012, 67:1041-1043.
13. Lepelletier D., Lucet J.C., Astagneau P., Coignard B., Vaux S., Rabaud C., et al. Résultats de l'enquête de la Société française d'hygiène hospitalière sur la prise en charge des patients suspects ou porteurs de bactéries hautement résistantes aux antibiotiques 2013, Bulletin SF2H, [consulté le 07/07/2014] Disponible sur http://www.sf2h.net/publications-SF2H/SF2H_enquete-BHR-2012.pdf.
14. Haut Conseil de la santé publique Commission spécialisée sécurité patient. Recommandations pour la prévention de la transmission croisée des « Bactéries Hautement Résistantes aux antibiotiques émergentes » (BHRe) 2014, Disponible sur http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=372.
15. Lepelletier D., Andremont A., Grandbastien B. Risk of highly resistant bacteria importation from repatriates and travelers hospitalized in foreign countries: about the French recommendations to limit their spread. J Travel Med 2011, 18:344-351. the National Working Group.
16. Paterson D.L., Bonomo R. Extended-spectrum ß-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
17. Canton R., Coque T.M. The CTX-M ß-lactamase pandemic. Curr Opin Microbiol 2006, 9:466-475.
18. Pitout J.D., Nordmann P., Laupland K.B., Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005, 56:52-59.
19. Zahar J.R., Lortholary O., Martin C., Potel G., Plesiat P., Nordmann P. Addressing the challenge of extended-spectrum ß-lactamases. Curr Opin Investig Drugs 2009, 10:172-180.
20. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
21. Vodovar D., Marcadé G., Raskine L., Malissin I., Mégarbane B. [Enterobacteriaceae producing extended spectrum beta-lactamase: epidemiology, risk factors, and prevention]. Rev Med Interne 2013, 34:687-693.
22. Nordmann P., Cuzon G., Naas T. The real threat of Klebsiella pneumonia carbapenemase producing bacteria. Lancet Infect Dis 2009, 9:228-236.
23. Poirel L., Pitout J.D., Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol 2007, 2:501-512.
24. Borer A., Eskira S., Nativ R., Saidel-Odes L., Riesenberg K., Livshiz-Riven I., et al. A multifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenem-resistant Klebsiella pneumoniae in Southern Israel. Infect Control Hosp Epidemiol 2011, 32:1158-1165.
25. Poirel L., Héritier C., Tolün V., Nordmann P. Emergence of oxacillinase-mediated resistance in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004, 48:15-22.
26. Gulmez D., Woodford N., Palepou M.F., Mushtaq S., Metan G., Yakupogullari Y., et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents 2008, 31:523-526.
27. Carrer A., Poirel L., Eraskoy H., Cagaty A.A., Badur S., Nordmann P. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother 2008, 52:2950-2954.
28. InVS Épisodes impliquant des entérobactéries productrices de carbapénémases en France: situation épidémiologique du 14 mars 2014 2014, Disponible sur http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Infections-associees-aux-soins/Surveillance-des-infections-associees-aux-soins-IAS/Enterobacteries-productrices-de-carbapenemases-EPC/Episodes-impliquant-des-enterobacteries-productrices-de-carbapenemases-en-France.
29. Dortet L., Bréchard L., Cuzon G., Poirel L., Nordmann P. Strategy for rapid detection of carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2014, 58:2441-2445.
30. Dortet L., Bréchard L., Poirel L., Nordmann P. Impact of the isolation medium for detection of carbapenemase-producing Enterobacteriaceae using an updated version of the Carba NP test. J Med Microbiol 2014, 63:772-776.
31. Cuzon G., Naas T., Bogaerts P., Glupczynski Y., Nordmann P. Evaluation of a DNA microarray for the rapid detection of extended-spectrum beta-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J Antimicrob Chemother 2012, 67:1865-1869.
32. Centre national de référence Résistance aux antibiotiques 2014, Disponible sur http://www.cnr-resistance-antibiotiques.fr/.
33. Société française d'hygiène hospitalière (SF2H) Prévention de la transmission croisée, 2009 2014, Disponible sur http://www.sf2h.net/publications-SF2H/SF2H_prevention-transmission-croisee-2009.pdf.
34. Ozorowski T., Kawalec M., Zaleska M., Konopka L., Hryniewicz W. The effect of an antibiotic policy on the control of vancomycin-resistant enterococci outbreak and on the resistance patterns of bacteria isolated from the blood of patients in a hematology unit. Pol Arch Med Wewn 2009, 119:712-718.
35. Steinmann J., Kaase M., Gatermann S., Popp W., Steinmann E., Damman M., et al. Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro Surveill 2011, 16. pii: 19944.
36. Christiansen K.J., Tibbett P.A., Beresford W., Pearman J.W., Lee R.C., Coombs G.W., et al. Eradication of a large outbreak of a single strain of vanB vancomycin-resistant Enterococcus faecium at a major Australian teaching hospital. Infect Control Hosp Epidemiol 2004, 25:384-390.
37. Kassis-Chikhani N., Saliba F., Carbonne A., Neuville S., Decre D., Sengelin C., et al. Extended measures for controlling an outbreak of VIM-1 producing imipenem-resistant Klebsiella pneumoniae in a liver transplant centre in France, 2003-2004. Euro Surveill 2010, 15. pii: 19713.
38. Akova M., Daikos G.L., Tzouvelekis L., Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 2012, 18:439-448.
39. Cohen M.J., Block C., Levin P.D., Schwartz C., Gross I., Weiss Y., et al. Institutional control measures to curtail the epidemic spread of carbapenem-resistant Klebsiella pneumoniae: a 4-year perspective. Infect Control Hosp Epidemiol 2011, 32:673-678.
40. Zarkotou O., Pournaras S., Tselioti P., Dragoumanos V., Pitiriga V., Ranellou K., et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011, 17:1798-1803.